Back to results
US 10,501,451 B2Granted
Selective NR2B antagonists
AssigneeBristol-Myers Squibb Company
InventorsImadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Srinivas Cheruku, Poornima Shetty, John E. Macor
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMD A) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.
Claims19
A compound of the formula I
- where:
- Ar1 is phenyl and is substituted with 0-3 substituent selected from cyano, halo, alkyl, haloalkyl and haloalkoxy;
- Ar2 is phenyl, pyridinyl or pyrimidinyl, and is substituted with 1 OR substituent and with 0-2 halo or alkyl substituents;
- R is hydrogen or a prodrug moiety selected from the group consisting of alkyl esters, amino acid esters, alkoxy esters, phosphonic acids, phosphonic alkyl esters, alkoxyphosphononate acid, alkoxyphosphonate alkyl esters, alkyl carabamates, amino acid carbamates, alkyl phosporamidates, aryl phosphoramidates, and sulfamates;
- X is a bond or C1-C3 alkylene;
- n is 1 or 2;
- ring A is piperidine or piperazine and is substituted with 0-1 halo substituents;
- or a pharmaceutically acceptable salt thereof.
5 more elements
A compound:
- or a pharmaceutically acceptable salt thereof.
A compound:
- or a pharmaceutically acceptable salt thereof
Dependencies are inferred from the claim text.